Get advice on how to evaluate the methodology of biomarker studies in an interview with James Coyne, PhD, clinical health psychologist, professor emeritus of in the psychiatry with University of Pennsylvania and professor of health psychology, University of Groningen, the Netherlands.
Read More
Assurex Health recently sent me an email inviting me to dine at Legal Seafood to learn about “Clinical Applications of Psychiatric Pharmacogenetics.” I didn’t go, but increasingly I am hearing from colleagues about their experiences at these dinner programs: “What do you think about this GeneSight test? The data looked pretty impressive at this dinner.”
Read More
Choosing the “right” treatment for a given patient involves a large number of factors, including personal preference—both the clinician’s and the patient’s. Is there a better way?
Read More
In October, 2015, The Boston Globe ran an article that picked up on The Carlat Psychiatry Report's coverage of the GeneSight test. It's a promising technology, but the marketing has leap-frogged ahead of the science.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
